8-KLeadership ChangesExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Sep 12, 2019)

Filed September 12, 2019For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) has filed an 8-K to announce significant changes to its Board of Directors. Effective upon the closing of the acquisition of Celgene Corporation, three new independent directors, Michael Bonney, Dr. Julia A. Haller, and Phyllis Yale, have been elected. This expansion increases the Board size to fourteen members and is designed to bring in diverse expertise relevant to the integration and future strategy of the combined entity. These appointments are crucial for governance as BMY integrates the substantial operations of Celgene. The new directors bring extensive experience in areas such as biopharmaceuticals, healthcare management, corporate strategy, and board leadership. Investors should view these additions as a positive step towards robust oversight and strategic guidance during a pivotal period for the company, particularly as the Celgene acquisition nears completion.

Key Highlights

  • 1Election of three new independent directors: Michael Bonney, Dr. Julia A. Haller, and Phyllis Yale.
  • 2Board size increased to fourteen members, effective upon the closing of the Celgene acquisition.
  • 3New directors bring diverse and relevant expertise in biopharmaceuticals, healthcare, strategy, and governance.
  • 4Appointed directors are deemed independent under NYSE and company standards.
  • 5Director compensation includes an annual retainer of $100,000 and a deferred share unit award valued at $185,000.
  • 6Michael Bonney currently serves on the Celgene Board of Directors.
  • 7The company is actively managing director board commitments, with Mr. Bonney committed to adhering to a policy limiting service on public company boards.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce the election of three new independent directors to Bristol-Myers Squibb's Board of Directors. These appointments are effective upon the closing of the company's acquisition of Celgene Corporation.

The new directors are Michael Bonney, Dr. Julia A. Haller, and Phyllis Yale. They bring significant experience in areas such as biopharmaceutical leadership, healthcare operations and strategy, corporate governance, and financial oversight, which are highly relevant to the integration of Celgene and BMY's future growth.

The expansion of the board and the addition of these directors with diverse backgrounds are intended to strengthen corporate governance and provide strategic oversight during the critical integration phase of the Celgene acquisition. Their independent perspectives can help guide the combined entity through complex challenges and opportunities.

Each of the new non-employee directors will receive compensation in accordance with the company's standard policy for non-employee directors, which includes an annual retainer of $100,000 and an annual award of deferred share units valued at $185,000 on the date of grant.